NCT01150760View on ClinicalTrials.gov

Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database

CompletedOBSERVATIONAL

Enrollment

7,050

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Ileus

Interventions

DRUG

Alvimopan

At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection

Trial Locations (1)

28208

Premier database, Charlotte

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01150760 - Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database | Biotech Hunter | Biotech Hunter